| Name | Title | Contact Details |
|---|
RevGen GENIUS stands as a premier source for aiding businesses in crafting a robust and efficient go-to-market (GTM) strategy. With our expert guidance, clients can drive revenue growth with confidence.
Why Wait? JOIN OUR REVOLUTION IN FURNITURE! Our mission is powerful and we execute with precision: Furnish your entire office with shipping in just 48 hours. With design support, 3D renders and fast quotes, you can say goodbye to the days of waiting 6-8 weeks (or more!) to furnish your office. Backed by a great warranty, you can count on us to deliver quality products, at rocket speeds. The stars have aligned for us to be your go-to furniture manufacturer! Stay connected here to learn about new products coming into our orbit this year and beyond.
Red Sea Consulting is a USA-based consulting company. Our mission is to provide a turn-key complete and comprehensive service to non-physicians to establish healthcare centers, especially urgent care centers, Mental Health, Pain Management, and Applied Behavioral Analysis, through a well-structured and themeless process.
Lacrosse Equpment
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.